Press releases

Klaria receives 25 MSEK in loan financing with the possibility of an additional 15 MSEK

Klaria Pharma Holding AB (publ) ("Klaria" or the "Company") announces that Klaria has entered into an agreement for a bridge loan of 25 MSEK from a Swedish finance company. The agreement also includes an option for the Company to borrow an additional 15 MSEK if necessary, which means that the total possible financing framework amounts to 40 MSEK.

Klaria adjusts annual report release date

Summons to the Annual General Meeting of Klaria Pharma Holding AB (publ)

With a change from what has been previously announced, the shareholders of Klaria Pharma Holding AB (publ), corporate registration number 556959–2917, are hereby invited to attend the Annual General Meeting to be held on 26 June 2026 at 10.00 a.m. CEST at Advokatfirman Glimstedt's Stockholm office, Sturegatan 46 in Stockholm.

Klaria postpones interim Q1 report

Klaria postpones publication of the annual report

Klaria Pharma Holding (publ) announces that the 2025 annual report will be published on May 29th.

Notice of the Annual General Meeting of Klaria Pharma Holding AB (publ)

The shareholders of Klaria Pharma Holding AB (publ), org.nr 556959–2917, are hereby invited to attend the Annual General Meeting to be held on 26 May 2026 at 10.00 a.m. CET at Advokatfirman Glimstedt's Stockholm office, Sturegatan 46 in Stockholm.

Annula Genernal Meeting Date Change:  Klaria Pharma Holding (publ)

Correction: Incorrect inclusion of MAR text in earlier release.Summary of extraordinary general meeting in Klaria Pharma Holding AB (publ)

Today, an extraordinary general meeting was held in Klaria Pharma Holding AB (publ), company registration number 556959-2917. Below is a summary of the resolutions adopted by the extra general meeting (all in accordance with the proposal presented in the notice convening the extra general meeting, which have been made available on the Company’s website www.klaria.com).

Summary of extraordinary general meeting in Klaria Pharma Holding AB (publ)

Today, an extraordinary general meeting was held in Klaria Pharma Holding AB (publ), company registration number 556959-2917. Below is a summary of the resolutions adopted by the extra general meeting (all in accordance with the proposal presented in the notice convening the extra general meeting, which have been made available on the Company’s website www.klaria.com).

Klaria Pharma Holding AB (publ) Summons to Extraordinary General Meeting

The shareholders of Klaria Pharma Holding AB (publ), org.nr 556959–2917, are hereby summoned to extraordinary general meeting on March 19, 2026, at 10.00 a.m. CET, at Advokatfirman Glimstedts Stockholm office, Sturegatan 46 in Stockholm.

Klaria accelerates its business development work in collaboration with BDO

With Klaria’s product, Sumatriptan Alginate Film, approved in the EU and set to launch in 2026 in the largest EU markets, the company has now engaged BDO LLP’s UK Life Sciences & Healthcare M&A team (‘BDO’) to support business development initiatives in strategically important markets. In line with this, several strategic options are being considered that may lead to different potential outcomes, all with the aim of maximizing shareholder value.

Klaria Receives Positive Opinion on Sumatriptan Oral Film Patent Application

Klaria announced earlier in the year that it had submitted an additional patent application on the sumatriptan oral film product to further protect the product and potentially extend its market exclusivity.  The International Search Authority (ISA), which informs the decisions of the European Patent Office (EPO) as well as many other international patent authorities has issued their report stating that all claims made in the application fulfill all requirements of patentability.

Klaria stengthens patent portfolio of sumatriptan alginate film with new filing

Klaria AB has filed a ‘third generation’ patent application to protect the sumatriptan alginate film product.  The current application, when granted, would give the product worldwide market exclusivity to 2045.